170 Views | 123 Downloads
Stephen F. Traynelis, 1510 Clifton Rd NE, Atlanta, GA, 30322, strayne@emory.edu, 404-727-0357
The authors contributed in the following manner: conceptualization (SFT, REP, SAS), data curation and formal analysis (REP, SAS, CS, AK, GFC, HY, SFT), funding acquisition (SAS, SFT, HY, DCL, GJB), investigation (REP, SAS, CS, AK, JZ, PL, EGA, GFC, MPE, DSM, PB), development or design of methodology (REP, SAS, SFT, EGA, GFC, MPE, GJB, DSM, DCL, LSL), project administration (REP, SFT, SAS), provision of reagents, materials, and analysis tools (PKRG, EGA, GFC, PB, GJB, MPE, DSM, DCL, LSL), software (REP, SFT), supervision (SFT, LSL, DCL, GJB), verification (REP, SAS, CS, AK, GFC, MPE, DSM), visualization and writing (all authors).
The authors thank Kevin Ogden for help with analytical software development.
SFT is a consultant for Janssen Pharmaceuticals Inc., is PI on a research grants from Janssen and Allergan to Emory University School of Medicine, is a member of the SAB for Sage Therapeutics, is co-founder of NeurOp Inc, and receives royalties for software. DCL is a member of the Board of Directors for NeurOp Inc. DCL, DSM, EGA, GFC, PKRG, LSL, MPE, SFT are co-inventors on Emory-owned Intellectual Property that includes allosteric modulators of NMDA receptor function. HY is PI on a research grant from Sage Therapeutics to Emory University School of Medicine.
This work was supported by the NINDS (NS065371, SFT), NICHD (HD082373, HY), NIMH (MH109026, GB), Citizens United for Research in Epilepsy (SAS) and the Emory University Research Committee (SAS).